This second episode in KDIGO’s four-part IgAN series addresses the treatment revolution in IgAN. Join Dana Rizk, MD (University of Alabama at Birmingham, US), and Shikha Wadhwani, MD (University of Texas Medical Branch, US) in understanding how disease pathophysiology is fueling a wave of new therapies that go beyond traditional supportive care.

Key topics include what's changed since the KDIGO 2021 Guideline, the four-hit hypothesis and its role in driving novel therapies, key factors to consider when selecting treatments, and the evolving role of traditional approaches alongside newer agents.

The first episode in this series (Episode #24) features KDIGO IgAN Guideline Co-Chair, Brad Rovin, MD (University of Ohio Medicine, US). Future episodes (Episode #29 and Episode #30) feature Shikha Wadwani, MD (Cedars Sinai, US), Andrew Lazar, MD (University Hospitals of Cleveland, US), Gaia Coppock, MD (University of Pennsylvania Medicine, US), and Suneel Udani, MD (Nephrology Associates of Northern Illinois and Indiana, US), and cover lessons from IgAN Case Files, and challenges and strategies to implementing KDIGO IgAN Guideline recommendations.

This podcast was supported by Travere.